Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Placebo

Tablets (n=4), 0 mg twice daily for 84 days

DRUG

25 mg PF-04991532

Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days

DRUG

75 mg PF-04991532

Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days

DRUG

150 mg PF-04991532

Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days

DRUG

300 mg PF-04991532

Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days

DRUG

Sitagliptin 100 mg

Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.

Trial Locations (42)

333

Pfizer Investigational Site, Taoyuan

6760

Pfizer Investigational Site, Kistelek

8230

Pfizer Investigational Site, Balatonfüred

19446

Pfizer Investigational Site, Lansdale

20234

Pfizer Investigational Site, Aguascalientes

23294

Pfizer Investigational Site, Richmond

23502

Pfizer Investigational Site, Norfolk

28277

Pfizer Investigational Site, Charlotte

33134

Pfizer Investigational Site, Coral Gables

34471

Pfizer Investigational Site, Ocala

40504

Pfizer Investigational Site, Lexington

40705

Pfizer Investigational Site, Taichung

45245

Pfizer Investigational Site, Cincinnati

46260

Pfizer Investigational Site, Indianapolis

54055

Pfizer Investigational Site, Tlalnepantla

55430

Pfizer Investigational Site, Brooklyn Center

58103

Pfizer Investigational Site, Fargo

66215

Pfizer Investigational Site, Overland Park

67010

Pfizer Investigational Site, Augusta

67207

Pfizer Investigational Site, Wichita

70601

Pfizer Investigational Site, Lake Charles

72205

Pfizer Investigational Site, Little Rock

75246

Pfizer Investigational Site, Dallas

77450

Pfizer Investigational Site, Katy

78229

Pfizer Investigational Site, San Antonio

80209

Pfizer Investigational Site, Denver

89101

Pfizer Investigational Site, Las Vegas

95661

Pfizer Investigational Site, Roseville

96814

Pfizer Investigational Site, Honolulu

04210

Pfizer Investigational Site, Auburn

08611

Pfizer Investigational Site, Trenton

V4A 2H9

Pfizer Investigational Site, Surrey

A0A 1G0

Pfizer Investigational Site, Bay Roberts

L6T 0G1

Pfizer Investigational Site, Brampton

L4Y 2N8

Pfizer Investigational Site, Mississauga

J7J 2K8

Pfizer Investigational Site, Mirabel

G3K 2P8

Pfizer Investigational Site, Québec

06700

Pfizer Investigational Site, Mexico City

851 01

Pfizer Investigational Site, Bratislava

915 01

Pfizer Investigational Site, Nové Mesto nad Váhom

902 01

Pfizer Investigational Site, Pezinok

080 01

Pfizer Investigational Site, Prešov

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01338870 - Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter